Wednesday, November 13, 2024

Q1 results today: ICICI Bank, Dr Reddy’s among 34 companies to announce earnings today

Saturday, July 27, 2024, 4:37
This news item was posted in Business category and has 0 Comments so far.

The first quarter earnings season is underway and as many as 34 companies will announce their results on Saturday. Key results to watch out include that of ICICI Bank, REC, Dr Reddy’s Labs and IDFC First Bank.Apart from the above, Finolex Industries, IEC Education, IFB Industries, J&K Bank, Jaiprakash Power, SBFC Finance, Vishal Fabrics, Spandana Sphoorty, Smruthi Organics, NTPC, Genus Power, Gujarat Cotex among others will also declare their June quarter results.ICICI Bank Q1 expectationsICICI Bank is expected to report a net profit for the quarter ended June 2024 in the range of Rs 10,441-10,876 crore, according to estimates by four brokerages. The growth in April-June quarter profit after tax (PAT) could be between 8.1% and 12.7% on a year-on-year basis.The net interest income (NII) for the reporting quarter is seen in the range of Rs 19,253-19,700 crore, which translates into an uptick of 5.2-8% on a year-on-year basis.PAT estimates are most conservative in case of JM Financial at Rs 10,441 crore (8.2%) while Yes remains most bullish at Rs 10,876 crore, seeing a 12.7% YoY growth. As for NII in the said quarter, Nomura’s figures remain most bullish at Rs 19,700 crore while JM’s numbers are most conservative at Rs 19,253 crore.On a sequential basis, PAT may be in the range between -2.6% and 1.6%, the estimates said. While Nomura sees PAT to remain flat QoQ, Kotak and JM see it decline to 2.6%. Yes Securities is the only one to have estimated a QoQ growth in PAT at 1.6%.Dr Reddy’s Q1 expectationsPharma major Dr Reddy’s is expected to have a benign first quarter, dragged down by weak US sales due to increased competition and pricing challenges.Net profit for the reporting quarter may decline 4% year-on-year, according to an average estimate of four brokerages, while revenues are seen rising 8% year-on-year.The subdued growth in US sales during the June 2024 quarter may be offset by higher Revlimid sales, analysts said.In the preceding March quarter, Dr Reddy’s reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue from operations rose 12% year-on-year to Rs 7,083 crore.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

You can leave a response, or trackback from your own site.

Leave a Reply